Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.

Cancer biology & therapy - 1 Jan 2018

Jin Min, Cai Jun, Wang Xuan, Zhang Tao, Zhao Yingchao

Abstract excerpt

Ovarian cancer is a most common lethal gynecological malignant tumor, with a gradual increasing incidence throughout the world. The mainstay treatment is cytoreductive surgery followed by platinum-based chemotherapy. However, a high percentage of patients recur, thus needing multiple treatments with a frequently poor prognosis. Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Maintenance Chemotherapy

Share to Neoplasm Staging

Share to Ovarian Neoplasms

Share to Pyridines

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 30110192
DOI: 10.1080/15384047.2018.1491500
PMCID: PMC6301803

Genes

ALK
BRAF
BRCA1
EGFR
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.PMID 30110192Read ↗

Apatinib in Treating Clinical and Biochemical Recurrent Ovarian CancerSemantic proximity Read ↗

Ovarian Cancer—Insights into Platinum Resistance and Overcoming ItSemantic proximity Read ↗

Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.Semantic proximity Read ↗

Successful treatment of Afatinib plus Apatinib using for a lung adenocarcinoma patient with HER-2 V659D mutation: a rare case report.Semantic proximity Read ↗

Systematic analysis of ovarian cancer platinum-resistance mechanisms via text miningSemantic proximity Read ↗

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.Semantic proximity Read ↗

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)Semantic proximity Read ↗

Durable Disease Control after Sequential Anlotinib Maintenance Therapy Following Local Radiotherapy in a Patient with Platinum-Refractory Recurrent Ovarian Clear Cell Carcinoma: A Case Report and Literature ReviewSemantic proximity Read ↗

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.Semantic proximity Read ↗

The role of niraparib for the treatment of ovarian cancer.Semantic proximity Read ↗

Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.Semantic proximity Read ↗

A Phase I Dose-Escalation Study of Lobaplatin Combined with Paclitaxel in Platinum-Sensitive Recurrent Ovarian Epithelial Carcinoma: Safety, Tolerability, and Preliminary Efficacy AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.